#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Waldenstrom's macroglobulinaemia recurrent Epilepsy with myoclonic-atonic seizures Idiopathic intracranial hypertension Diffuse large B-cell lymphoma refractory Congenital cystic kidney disease Peripheral T-cell lymphoma unspecified Intracranial germ cell tumour Hereditary angioedema Hypochromic anaemia Antiphospholipid syndrome Muscular dystrophy Cardiac sarcoidosis Leber's congenital amaurosis Myeloproliferative neoplasm Langerhans cell sarcoma More trials…

    Learn about Rare Diseases

    Retinoblastoma – Trials in Disease Tuberous sclerosis complex – Treatment Pelizaeus-Merzbacher disease – Trials in Disease Focal segmental glomerulosclerosis – Diagnostics KBG syndrome – Trials in Disease Chondrosarcoma Alveolar rhabdomyosarcoma – Diagnostics Mast cell activation syndrome – Life with Disease Myxofibrosarcoma – Basic Information Isodicentric chromosome 15 syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Codeine Phosphate Hemihydrate Avibactam Auto4 Zongertinib Mcla-129 Ibuprofen Lysine Forimtamig Vibostolimab Rbp030.2 Ianalumab Albaconazole Sodium Chloride Nitric Oxide SODIUM IBANDRONATE Iclepertin MEGESTROL ACETATE 204-NETU JNJ-75276617 Mezigdomide Staphylococcus Aureus More therapies…

    Learn about Your Condition

    Skin papilloma Endocarditis bacterial Diabetic foot infection Encephalitis autoimmune Femoral neck fracture Coma Gastrectomy Infectious pleural effusion Laryngeal cancer stage I Diarrhoea Urticaria chronic Major depression Mite allergy Medulloblastoma Metastatic malignant melanoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study on the Safety and Efficacy of Cevostamab with Lenalidomide or Iberdomide for Patients with High-Risk or Relapsed Multiple Myeloma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Cevostamab
    • Iberdomide
    • Lenalidomide
    France Germany Poland Spain

  • Study on Dexamethasone for Patients with Advanced Relapsed or Refractory Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone
    France

  • Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Bortezomib
    • Daratumumab
    • Dexamethasone
    Austria Belgium Czechia Denmark Finland France +6

  • Study of Ciltacabtagene Autoleucel and Drug Combination for Treatment of High-Risk Smoldering Multiple Myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Ciltacabtagene Autoleucel
    • Fludarabine
    • Bortezomib
    Spain

  • Study on the Safety and Effectiveness of HDP-101 for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Hdp-101
    Germany Hungary Poland Romania Spain

  • Study on the Safety and Effectiveness of Teclistamab and Talquetamab for Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Talquetamab
    • Betamethasone Sodium Phosphate
    • Teclistamab
    Germany
Previous Page
1 2 3 4 5 6 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!